
Precision BioSciences Announces Q2 2025 Financial Results and Business Highlights
Precision BioSciences Reports Second Quarter 2025 Financial Results, Highlights Strong Clinical Progress in Gene Editing Programs, and Extends Cash Runway Into 2027 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology…












